TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03584906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TDT harvesting approach
Description: A connective tissue graft is harvested from the palate after reflecting a primary palatal flap

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MT harvesting approach
Description: An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage procedure
Description: A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage procedure
Description: A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
Study: NCT03834441

Intervention type: OTHER
Group type: OTHER
Intervention: Written HRSN screening
Description: Patient completes written screen on iPad.
Study: NCT02256631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by subcutaneous injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by subcutaneous injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by subcutaneous injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01LS
Description: Administered by subcutaneous injection in the thigh
Study: NCT03584906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage procedure
Description: A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage procedure
Description: A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
Study: NCT02869321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl placebo
Study: NCT02256631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01LS
Description: Administered by subcutaneous injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by subcutaneous injection in the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: Administered by subcutaneous injection in the thigh
Study: NCT00957580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Study: NCT03711461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endotracheal tube (double lumen)
Description: patients routinely use double lumen endotracheal intubation while they have received thoracoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nonintubated
Description: patients receiving nonintubated anesthetic plan while they have received thoracoscopy
Study: NCT04173585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
Study: NCT02869321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrostomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gastrostomy
Study: NCT04346511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.
Study: NCT01470222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
Study: NCT01506024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty direct lateral approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty posterior approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty, anterior approach
Study: NCT03637283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anti-VEGF
Description: vitreoretinal surgery combined with intraoperative anti-VEGF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fan-shaped photocoagulation
Description: vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
Study: NCT01963988

Intervention type: PROCEDURE
Intervention: Transurethral Coagulation (TUC)

Intervention type: PROCEDURE
Intervention: Transurethral Resection(TUR)
Study: NCT03320187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroderm TTS
Description: Transdermal nitroglycerin 5mg skin patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dinoprostone
Description: Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
Study: NCT01135992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
Study: NCT02184598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: 12 weeks of cognitive training; 4 sessions/week; duration 30 min

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cognitive training
Description: In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
Study: NCT03245346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEA
Description: Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCEA
Description: Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: GA
Description: General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.

Intervention type: DRUG
Group type: OTHER
Intervention: PCIA
Description: Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
Study: NCT02852967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching belumosudil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching belumosudil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching belumosudil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching belumosudil
Study: NCT02903823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen bolus injection
Description: A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
Study: NCT01129492

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level Laser therapy
Description: A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low-level Laser therapy
Description: A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
Study: NCT00106041

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Veterans Integrated Palliative Care Nurse Case Manager
Description: Palliative Care nurse case management
Study: NCT02690766

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Behavioral Weight Change Intervention
Description: Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
Study: NCT02501837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon-Spray
Description: Intranasal administration of 24 IU Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon-Spray
Description: Intranasal administration of 24 IU Oxytocin
Study: NCT04320290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Acting Antivirals
Description: 8 weeks of DAA treatment
Study: NCT02960633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corail with collar.
Study: NCT02399722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WICVAC
Description: combined wound therapy
Study: NCT02960633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corail without collar.
Study: NCT02399722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VAC mono therapy
Description: mono therapy
Study: NCT01245621

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Later entry group
Description: 1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan.
Study: NCT03549286

Intervention type: OTHER
Intervention: Questionnaire passation
Description: Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
Study: NCT04602143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
Study: NCT05399927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
Study: NCT00066612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Irinotecan will be given 250 mg/m\^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
Study: NCT02499627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
Study: NCT03712774

Intervention type: OTHER
Intervention: EORTC QLQ C30
Description: standardized questionaire

Intervention type: OTHER
Intervention: EORTC QLQ C30
Description: standardized questionaire
Study: NCT01245621

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early palliative care intervention
Description: 1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan.
Study: NCT04945122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4mg Qn

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20mg Qn
Study: NCT03466307

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasonographic examination of shoulder
Study: NCT03712774

Intervention type: OTHER
Intervention: EORTC QLQ OES-18
Description: standardized questionaire

Intervention type: OTHER
Intervention: EORTC QLQ OES-18
Description: standardized questionaire

Intervention type: OTHER
Intervention: EORTC OG-25
Description: standardized questionaire

Intervention type: OTHER
Intervention: EORTC OG-25
Description: standardized questionaire
Study: NCT03299478

Intervention type: OTHER
Intervention: Will look for immune infiltration
Study: NCT01007175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 10 mg q4wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 30 mg q4wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
Study: NCT03466307

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasonographic examination of shoulder

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasonographic examination of shoulder
Study: NCT01007175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 80 mg q4wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 10 mg q8wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATN-103 80 mg q8wks
Description: ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
Study: NCT02476604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coaching and electronic messaging
Description: Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
Study: NCT00704067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported employment plus cognitive training
Description: Supported employment for 12 months plus cognitive training for the first 12 weeks
Study: NCT03691259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballet Classes
Description: Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
Study: NCT01388738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citicoline
Description: citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os
Study: NCT00704067

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced supported employment
Description: Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
Study: NCT00925002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafamidis
Description: 20 mg oral Fx-1006A daily
Study: NCT03757429

Intervention type: OTHER
Intervention: RS-virus infection
Description: The intervention consists of lower respiratory tract infection due to RS-virus

Intervention type: OTHER
Intervention: RS-virus infection
Description: The intervention consists of lower respiratory tract infection due to RS-virus
Study: NCT03012334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Dose is based on treatment sequence in 5-way crossover

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Dose is based on treatment sequence in 5-way crossover

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Dose is based on treatment sequence in 5-way crossover

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Active comparator based on treatment sequence in 5-way crossover
Study: NCT01388738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Alpha glycerylphosphorylcholine
Description: choline alfoscerate IV 1000mg daily 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cerebrolysin
Description: Cerebrolysin IV 10 ml daily 10 days
Study: NCT00454896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VESIcare®
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral